1. Home
  2. GECC vs GANX Comparison

GECC vs GANX Comparison

Compare GECC & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GECC

Great Elm Capital Corp.

HOLD

Current Price

$5.55

Market Cap

73.8M

Sector

Finance

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.97

Market Cap

78.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GECC
GANX
Founded
2016
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.8M
78.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
GECC
GANX
Price
$5.55
$1.97
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$10.75
$7.50
AVG Volume (30 Days)
57.3K
532.0K
Earning Date
04-30-2026
05-13-2026
Dividend Yield
21.62%
N/A
EPS Growth
N/A
31.46
EPS
N/A
N/A
Revenue
N/A
$55,180.00
Revenue This Year
$0.92
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.63
$1.41
52 Week High
$11.45
$4.34

Technical Indicators

Market Signals
Indicator
GECC
GANX
Relative Strength Index (RSI) 57.11 47.16
Support Level $4.85 $1.66
Resistance Level $7.07 $2.11
Average True Range (ATR) 0.19 0.14
MACD 0.08 0.02
Stochastic Oscillator 78.26 51.09

Price Performance

Historical Comparison
GECC
GANX

About GECC Great Elm Capital Corp.

Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generates both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses. The Company operates as a single reportable segment with an investment objective to generate both current income and capital appreciation through debt and equity investments and manages the business on a consolidated basis.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Share on Social Networks: